行业分析 |
|
|
|
|
全球微生态药物研发现状及发展趋势 * |
高倩1,**(),张宏翔2,3,江洪1,叶茂1 |
|
Current Status and Trend of R&D of Microecological Drugs |
GAO Qian1,**(),ZHANG Hong-xiang2,3,JIANG Hong1,YE Mao1 |
3 Chinese Society of Biotechnology,Beijing 100101, China |
引用本文:
高倩,张宏翔,江洪,叶茂. 全球微生态药物研发现状及发展趋势 *[J]. 中国生物工程杂志, 2020, 40(1-2): 166-173.
GAO Qian,ZHANG Hong-xiang,JIANG Hong,YE Mao. Current Status and Trend of R&D of Microecological Drugs. China Biotechnology, 2020, 40(1-2): 166-173.
链接本文:
https://manu60.magtech.com.cn/biotech/CN/10.13523/j.cb.1905035
或
https://manu60.magtech.com.cn/biotech/CN/Y2020/V40/I1-2/166
|
[1] |
施慧琳, 王玥, 苏燕 , 等. 人类微生物组产业发展态势及建议. 中国生物工程杂志, 2019,39(6):97-103.
|
|
Shi H L, Wang Y, Su Y , et al. The development trend and suggestions of human microbiome industry. China Biotechnology, 2019,39(6):97-103.
|
[2] |
4D pharma acquires Tucana Health. [2016-2-10]. http://www.stockmarketwire.com/article/5210430/4D-ph-arma-acquires-Tucana-Health.html.
|
[3] |
Ferring acquires innovative biotechnology company and microbiome pioneer Rebiotix Inc. [2018-4-5]. https://www.rebiotix.com/news-media/press-releases/ferring-acquires-innovative-biotechnology-company-and-microbiome-pioneer-rebiotix-inc/.
|
[4] |
Lagier J C, Cadoret F, Raoult D . Critical microbiological view of SER-109. The Journal of Infectious Diseases, 2017,215(1):161-162.
|
[5] |
Collins J, Auchtung J M . Control of Clostridium difficile infection by defined microbial communities // Robert A B, Patrice D C. Bugs as Drugs: Therapeutic Microbes for the Prevention and Treatment of Disease.Washington:ASM. 2018.
|
[6] |
OxThera initiates extension part of a phase 3 study of oxabact in primary hyperoxaluria. [2019-6-20]. https://www.prnewswire.com/news-releases/oxthera-initiates-extension-part-of-a-phase-3-study-of-oxabact-in-primary-hyperoxaluria-300871682.html.
|
[7] |
Blount K F, Shannon W D, Deych E , et al. Restoration of bacterial microbiome composition and diversity among treatment responders in a phase 2 trial of RBX2660: An investigational microbiome restoration therapeutic. Open Forum Infectious Diseases, 2019, 6(4): ofz095.
|
[8] |
Mische S, Orenstein R, Dubberke E R . et al. 1950. Prevention of recurrent clostridium difficile at six months following treatment with microbiota-based therapy RBX2660: durability results from a phase 2 open-label study. Open Forum Infectious Diseases, 2018,5(Suppl 1):S562-S563.
|
[9] |
Allergan enters into licensing agreement with assembly biosciences to obtain worldwide rights to microbiome gastrointestinal development programs. [2017-1-9]. https://www.prnewswire.com/news-releases/allergan-enters-into-licensing-agreement-with-assembly-biosciences-to-obtain-worldwide-rights-to-microbiome-gastrointestinal-development-programs-300387518.html.
|
[10] |
Nestle Health Science makes latest move in breakthrough microbiome field. [2016-1-11]. https://www.nestlehealthscience.com/newsroom/press-releases/strategic-collaboration.
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|